13F Holdings
中文EN

PHVS Pharvaris N.V. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1830487 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-30.9%
TTM EPS YoY-19.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-65.2%
ROA-59.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets10.0%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-13.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense124.48M98.56M65.58M57.38M35.79M
SG&A expense45.34M47.12M31.34M29.34M18.35M
Operating income-173.71M-132.40M-99.83M-75.65M-42.66M
Interest expense———16,105267,510
Pretax income-173.71M-132.40M-99.83M-75.65M-42.66M
Income tax1.99M1.83M1.05M679,08770,117
Net income-175.70M-134.22M-100.88M-76.33M-42.70M
EPS (basic)-2.97-2.48-2.63-2.27-1.40
EPS (diluted)-2.97-2.48-2.63-2.27-1.40
Weighted avg. shares (diluted)59.16M54.02M38.39M33.59M30.41M
Banking
Net interest income6.54M5.47M224,494-16,105-267,510
Balance sheet
Cash & equivalents291.68M280.73M391.23M161.84M209.35M
Receivables4.55M2.94M1.04M382,468700,079
PP&E, netmay include right-of-use assets (IFRS)642,470667,000223,678193,474108,098
Total assets301.45M291.37M398.69M167.73M212.09M
Total liabilities30.18M23.61M14.65M18.47M7.14M
Shareholders' equity271.27M267.76M384.05M149.26M204.95M
Cash flow statement
Operating cash flow-137.07M-120.13M-93.05M-67.16M-44.60M
Capital expenditure164,619538,08689,984124,296130,032
Free cash flow-137.24M-120.67M-93.14M-67.29M-44.73M
Investing cash flow-164,619-538,086-89,984-124,296-130,032
Financing cash flow160.61M2.68M325.39M8.65M143.67M
Stock-based compensation19.05M16.21M10.66M11.35M8.20M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.